Choi Munseok, Kim Na Won, Hwang Ho Kyoung, Lee Woo Jung, Kang Chang Moo
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul 03722, Korea.
Yonsei University of Medical Library, Seoul 03722, Korea.
J Clin Med. 2020 Dec 5;9(12):3945. doi: 10.3390/jcm9123945.
The mainstream treatment for recurrent pancreatic cancer is potent chemotherapy or chemoradiotherapy. However, recent clinical investigations have suggested a potential oncologic role of local resection of recurrent pancreatic cancer. This systemic review with a pooled analysis aimed to assess the potential role of local repeated pancreatectomy with respect to the survival outcomes for patients with recurrent pancreatic ductal adenocarcinoma (PDAC) in the remnant pancreas. The PubMed database was searched, and 15 articles reporting on repeated pancreatectomy for local recurrence of PDAC in the remnant pancreas were identified. The pooled individual data were examined for the clinical outcomes of repeated pancreatectomy for recurrent PDAC. The survival analysis was performed using the Kaplan-Meier method. In the pooled analysis, the mean time interval from initial pancreatectomy to repeated pancreatectomy was 41.3 months (standard deviation (SD), 29.09 months). Completion total pancreatectomy was most commonly performed as repeated pancreatectomy (46 patients, 92.0%), and partial pancreatic resection was performed for only 4 (10.3%) patients. Twenty (40.9%) patients received postoperative chemotherapy following repeated pancreatectomy. The median overall survival was 60 months (95% confidential interval (CI): 45.99-74.01) after repeated pancreatectomy for isolated local recurrence in the remnant pancreas. Overall survival was markedly longer considering the timing of the initial pancreatectomy for pancreatic cancer (median, 107 months (95% CI: 80.37-133.62). The time interval between the initial and subsequent repeated pancreatectomy for pancreatic cancer was not associated with long-term oncologic outcomes ( = 0.254). Repeated pancreatectomy cannot completely replace adjuvant chemotherapy but should be considered for patients with isolated local recurrent PDAC in the remnant pancreas.
复发性胰腺癌的主流治疗方法是强效化疗或放化疗。然而,最近的临床研究表明,复发性胰腺癌局部切除可能具有肿瘤学作用。这项系统评价及汇总分析旨在评估局部重复胰腺切除术对残余胰腺中复发性胰腺导管腺癌(PDAC)患者生存结局的潜在作用。检索了PubMed数据库,确定了15篇关于在残余胰腺中对PDAC局部复发进行重复胰腺切除术的文章。对汇总的个体数据进行检查,以了解复发性PDAC重复胰腺切除术的临床结局。使用Kaplan-Meier方法进行生存分析。在汇总分析中,从初次胰腺切除术到重复胰腺切除术的平均时间间隔为41.3个月(标准差(SD),29.09个月)。最常进行的重复胰腺切除术是全胰腺切除术(46例患者,92.0%),仅4例(10.3%)患者进行了部分胰腺切除术。20例(40.9%)患者在重复胰腺切除术后接受了术后化疗。对于残余胰腺中孤立性局部复发进行重复胰腺切除术后,中位总生存期为60个月(95%置信区间(CI):45.99 - 74.01)。考虑到胰腺癌初次胰腺切除术的时间,总生存期明显更长(中位,107个月(95%CI:80.37 - 133.62))。胰腺癌初次和随后重复胰腺切除术之间的时间间隔与长期肿瘤学结局无关(P = 0.254)。重复胰腺切除术不能完全替代辅助化疗,但对于残余胰腺中孤立性局部复发的PDAC患者应予以考虑。